The company said reported revenue for Q2 was $1.645 billion, of which organic revenue was $828 million (up 7% as reported and 9% in constant currency), and revenue from the acquired Biosciences and Diagnostic Solutions businesses was $817 million.

1. 01

   The company said reported revenue for Q2 was $1.645 billion, of which organic revenue was $828 million (up 7% as reported and 9% in constant currency), and revenue from the acquired Biosciences and Diagnostic Solutions businesses was $817 million.

2. 02

   Waters reported a GAAP diluted loss per share of $1.39 for Q2, compared with diluted EPS of $2.47 a year earlier. The company said the result reflected purchase accounting charges from the acquisition, including amortization of acquired intangibles and inventory step-up. Adjusted EPS rose 3% to $3.05.

3. 03

   The company reported net cash provided by operating activities of $198 million for the 6 months ended July 4, 2026, compared with $301 million a year earlier, and adjusted non-GAAP free cash flow of $161 million, compared with $392 million a year earlier.

4. 04

   The company said it raised all components of its full-year guidance. It now expects full-year organic constant currency revenue growth of 7.0% to 9.0%, acquired business reported revenue of about $3.045 billion, and adjusted EPS of $14.45 to $14.65, representing 10% to 12% growth year over year.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.